Analyst Ratings For Merus Labs International (TSE:MSL)
Today, Scotiabank raised its price target on Merus Labs International (TSE:MSL) to C$1.65 per share.
There are 4 hold ratings, 1 buy rating on the stock.
The current consensus rating on Merus Labs International (TSE:MSL) is Hold (Score: 2.20) with a consensus target price of C$1.95 per share, a potential .
Some recent analyst ratings include
- 2/13/2017-Bloom Burton Reiterated Rating of Hold.
About Merus Labs International (TSE:MSL)
Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.
Recent Trading Activity for Merus Labs International (TSE:MSL)
Shares of Merus Labs International closed the previous trading session at 1.62 0.00 0.00% with shares trading hands.
